www.fdanews.com/articles/184449-seattle-genetics-wins-expanded-label-for-lymphoma-drug
![ApprovedGreen.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/ApprovedGreen.gif?t=1576044289&width=430)
Seattle Genetics Wins Expanded Label for Lymphoma Drug
November 16, 2017
FDA expanded the label of Seattle Genetics’ Adcetris (brentuximab vedotin), approving its use in treating primary cutaneous anaplastic large-cell lymphoma and CD30-expressing mycosis fungoides, a common form of the disease.
The agency approved the expanded indication for the cancer drug a month before its Dec. 16 action date.
Adcetris was previously approved for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The approval derived from positive data from a Phase III trial as well as two Phase II trials.